Theralase Technologies Inc.
Other OTCTotal Valuation
Theralase Technologies Inc. carries a market capitalization of 47.31M, placing it among publicly traded companies globally. Its enterprise value stands at 71.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 47.31M |
| Enterprise Value | 71.76M |
Share Statistics
Theralase Technologies Inc. currently has 275.60M shares outstanding.
| Shares Outstanding | 275.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 84.32, and the price-to-book ratio stands at -3.43.
| PE Ratio | N/A |
| PS Ratio | 84.32 |
| PB Ratio | -3.43 |
| P/TBV Ratio | 37.10 |
| P/FCF Ratio | -22.66 |
| P/OCF Ratio | -22.77 |
Enterprise Valuation
| EV / Sales | 83.65 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Theralase Technologies Inc. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.13, indicating elevated leverage, while an interest coverage ratio of -67.36 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.37 |
| Quick Ratio | 1.01 |
| Debt / Equity | 22.13 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -67.36 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -107.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.60 |
Stock Price Statistics
Theralase Technologies Inc.'s stock has gained approximately 14.28571% over the past 52 weeks. The 50-day moving average sits at 0.20, while the 200-day moving average is 0.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | 14.28571% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.17 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Theralase Technologies Inc. generated 857,912.00 in revenue and converted that into -3.68M in net income, yielding earnings per share of -0.01. EBITDA reached -3.46M, while operating income came in at -3.72M.
| Revenue | 857,912.00 |
| Gross Profit | 558,221.00 |
| Operating Income | -3.72M |
| Pretax Income | -3.68M |
| Net Income | -3.68M |
| EBITDA | -3.46M |
| EBIT | -3.72M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Theralase Technologies Inc. holds 1.00M in cash and equivalents against 431,585.00 in total debt, resulting in a net debt position of -748,008.00. Total book value stands at -21.10M, with working capital of 685,525.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.00M |
| Total Debt | 431,585.00 |
| Net Debt | -748,008.00 |
| Equity (Book Value) | -21.10M |
| Book Value Per Share | -0.08 |
| Working Capital | 685,525.00 |
Cash Flow
Theralase Technologies Inc. produced -3.18M in operating cash flow over the past twelve months. After subtracting 14,744.00 in capital expenditures, free cash flow totaled -3.16M - equivalent to -0.01 per share.
| Operating Cash Flow | -3.18M |
| Capital Expenditures | 14,744.00 |
| Free Cash Flow | -3.16M |
| FCF Per Share | -0.01 |
Margins
Theralase Technologies Inc. operates with a gross margin of 65.07, reflecting its pricing power and cost economics. The operating margin of -433.40 and net profit margin of -429.11 provide insight into operational efficiency.
| Gross Margin | 65.07 |
| Operating Margin | -433.40 |
| Pretax Margin | -429.11 |
| Profit Margin | -429.11 |
| EBITDA Margin | -403.12 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.58 |
| FCF Yield | -4.41 |
Scores
Theralase Technologies Inc. posts an Altman Z-Score of -6.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.50 |